Showing results (451-460 of 467) with videos related to

Sort By:
Pageof 47
The Journal of Dermatology|March 15, 2016
The wound/burn guidelines - 1: Wounds in generalYuji Inoue, Minoru Hasegawa, Takeo Maekawa, et al.
Cancer Medicine|August 16, 2023
Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study)Kenjiro Namikawa, Takamichi Ito, Shusuke Yoshikawa, et al.
The Journal of Dermatology|March 15, 2016
The wound/burn guidelines - 5: Guidelines for the management of lower leg ulcers/varicose veinsTakaaki Ito, Ryuichi Kukino, Masakazu Takahara, et al.
Nature|January 22, 2025
Immune evasion through mitochondrial transfer in the tumour microenvironmentHideki Ikeda, Katsushige Kawase, Tatsuya Nishi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2024
Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapySarah K Jacques, Janet McKeown, Piyush Grover, et al.
The Journal of Dermatology|July 7, 2026
Efficacy of Adjuvant Interferon-β Versus Observation for Resected Nail Apparatus Melanoma: A Multicenter Retrospective StudyTakaya Komori, Eiji Nakano, Yukiko Kiniwa, et al.
The Journal of Dermatology|May 5, 2022
Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN)Anna Kamimura, Yasuhiro Nakamura, Tatsuya Takenouchi, et al.
JCO Global Oncology|April 4, 2025
Adjuvant Anti-PD-1 Monotherapy Versus Observation for Stage III Acral Melanoma of the Sole: A Multicenter Retrospective Study in Japanese PatientsShigeru Koizumi, Naoya Yamazaki, Yuki Ichigozaki, et al.
Surgery|July 23, 2025
Prognosis of a deep excision margin within or beyond subcutaneous fat for invasive acral melanoma of the sole: A multi-institutional retrospective studyShigeru Koizumi, Naoya Yamazaki, Yuki Ichigozaki, et al.
Eclinicalmedicine|November 15, 2023
Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in <i>BRAF</i> V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyXue Bai, Ahmed Shaheen, Charlotte Grieco, et al.
Pageof 47